Medicinal Fungi Evidence Update

Participants used one application daily for 21 days, followed by alternate-day use for five months. Persistent cases could receive another six-month cycle. The prospective, open-label, non-comparative study enrolled 524 adults at 45 Greek sites; 494 completed follow-up.

Lesion regression was reported in 72.1% at six months and 75.9% overall. HPV clearance was reported in 72.0% of the 236 participants with suitable paired testing. Only 22 participants had paired baseline and 12-month biopsies. Two non-serious, possibly product-related adverse events were reported.

The large cohort and high retention are useful, but the absence of an untreated or placebo group is decisive: low-grade lesions and HPV can resolve spontaneously. HPV assays varied between sites and histological follow-up was sparse. The study therefore records outcomes during use; it cannot determine how much the gel caused them.

Evidence belongs to the complete formulation — not turkey tail, PSK, PSP, oral mushroom products or Coriolus generally. The work was funded by ELPEN Pharmaceutical; company employees were co-authors and several investigators received fees or support.

No qualifying systematic review or meta-analysis was identified. A newly indexed psychiatric narrative review mentioned Hericium erinaceus, but supplied no new quantitative synthesis or intervention-specific clinical conclusion.

Mice received G. lucidum spore oil at 800 mg/kg/day for 82 days. The study reported reductions in weight gain, fasting glucose, blood lipids and inflammatory markers, accompanied by microbiome, short-chain-fatty-acid and bile-acid changes. Fecal fermentation and HepG2 experiments explored possible microbiota-related mechanisms.

Only one dose was tested. Sample size, allocation, blinding, fungal strain, oil-production method and chemical standardisation were absent from the indexed abstract. Microbiome associations do not establish microbial causation, and this mouse dose cannot be translated directly into a human supplement claim. Funding came from Chinese public research programmes.

An authenticated maitake fruiting-body lot underwent repeated hot-water extraction, ethanol precipitation, ion-exchange purification and ultrafiltration. The nominally below-1-kDa PP-3 fraction had an apparent mass near 184 Da and 15.72% residual protein. It is more accurately described as an oligosaccharide-rich fraction than a conventional polysaccharide.

PP-3 gave the strongest tumour-cell and macrophage assay effects, but concentrations were high and the study lacked normal-cell controls, established anticancer comparators and endotoxin testing. For distribution work, chemically FITC/iodine-labelled material was given orally at 1 g/kg to ten rats; ten controls received saline. Calculated blood absorption peaked at 5.25% after two hours, with iodine signals mainly in liver and kidney.

ICP-MS detected iodine, not intact native PP-3, and labelling could alter distribution. The work demonstrates neither oral maitake absorption nor anticancer efficacy; it is instead a useful lesson in evidence ownership and chemically altered tracers.